111 related articles for article (PubMed ID: 11905547)
21. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD.
Cazzola M; Matera MG; Di Perna E; Califano C; D'Amato M; Mazzarella G
Respir Med; 1999 Dec; 93(12):909-11. PubMed ID: 10653054
[TBL] [Abstract][Full Text] [Related]
22. [Effects of oxitropium bromide on exercise and lung function in patients with pulmonary emphysema].
Nakanishi N; Ueda N; Kitade M; Moritaka T; Kamei T
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jan; 35(1):38-42. PubMed ID: 9071154
[TBL] [Abstract][Full Text] [Related]
23. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
24. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial).
Bellia V; Foresi A; Bianco S; Grassi V; Olivieri D; Bensi G; Volonté M;
Respir Med; 2002 Nov; 96(11):881-9. PubMed ID: 12418585
[TBL] [Abstract][Full Text] [Related]
26. Comparison between fenoterol and fenoterol plus oxitropium bromide delivered by metered-dose inhaler with InspirEase to relieve acute asthma attack.
Kamei T; Fujita J; Okada H; Nakamura H; Kishimoto T; Momoi A; Kawaji K; Yoshinouchi T; Ueda N; Takahara J
J Asthma; 1999; 36(1):67-75. PubMed ID: 10077137
[TBL] [Abstract][Full Text] [Related]
27. Bronchodilator responsiveness in patients with COPD.
Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S
Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
29. Tolerance to bronchodilating effects of salmeterol in COPD.
Donohue JF; Menjoge S; Kesten S
Respir Med; 2003 Sep; 97(9):1014-20. PubMed ID: 14509555
[TBL] [Abstract][Full Text] [Related]
30. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
31. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
32. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.
Wadbo M; Löfdahl CG; Larsson K; Skoogh BE; Tornling G; Arweström E; Bengtsson T; Ström K;
Eur Respir J; 2002 Nov; 20(5):1138-46. PubMed ID: 12449166
[TBL] [Abstract][Full Text] [Related]
33. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
Celli B; ZuWallack R; Wang S; Kesten S
Chest; 2003 Nov; 124(5):1743-8. PubMed ID: 14605043
[TBL] [Abstract][Full Text] [Related]
34. The functional impact of adding salmeterol and tiotropium in patients with stable COPD.
Cazzola M; Centanni S; Santus P; Verga M; Mondoni M; di Marco F; Matera MG
Respir Med; 2004 Dec; 98(12):1214-21. PubMed ID: 15588043
[TBL] [Abstract][Full Text] [Related]
35. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
36. Anticholinergic agents in asthma and COPD.
Gross NJ
Eur J Pharmacol; 2006 Mar; 533(1-3):36-9. PubMed ID: 16488410
[TBL] [Abstract][Full Text] [Related]
37. Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide.
Matsuyama W; Mitsuyama H; Koreeda Y; Higashimoto I; Osame M; Arimura K
Intern Med; 2007; 46(17):1373-9. PubMed ID: 17827835
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.
Tashkin D; Kesten S
Chest; 2003 May; 123(5):1441-9. PubMed ID: 12740259
[TBL] [Abstract][Full Text] [Related]
40. Long-term effect of the beta2-receptor agonist procaterol on daily life performance and exercise capacity in patients with stable chronic obstructive pulmonary disease. Clinical study with special reference to health-related quality of life and activities of daily living.
Shioya T; Satake M; Sato K; Sano MA; Sugawara K; Takahashi H; Honma M
Arzneimittelforschung; 2008; 58(1):24-8. PubMed ID: 18368947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
